[HTML][HTML] Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism

…, Y Rosenberg, CS Eby, SR Deitcher… - … England Journal of …, 2003 - Mass Medical Soc
Background Standard therapy to prevent recurrent venous thromboembolism includes 3 to
12 months of treatment with full-dose warfarin with a target international normalized ratio (INR…

[HTML][HTML] Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine

JA Silverman, SR Deitcher - Cancer chemotherapy and pharmacology, 2013 - Springer
Vincristine (VCR) is a mainstay of treatment of hematologic malignancies and solid tumors
due to its well-defined mechanism of action, demonstrated anticancer activity and its ability to …

Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day …

SR Deitcher, CM Kessler, G Merli… - Clinical and applied …, 2006 - journals.sagepub.com
This study evaluated enoxaparin alone versus initial enoxaparin followed by warfarin in
secondary prevention of venous thromboembolic events in adults with active malignancy. …

Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review

MPV Gomes, SR Deitcher - Archives of internal medicine, 2004 - jamanetwork.com
Venous thromboembolic events (VTEs) represent a serious complication related to
hormonal contraception and hormone replacement therapy (HRT). Evidence on hormonal …

[HTML][HTML] High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome–negative acute lymphoblastic …

…, JA Silverman, D Thomas, SR Deitcher… - Journal of clinical …, 2013 - ncbi.nlm.nih.gov
Purpose Relapsed adult acute lymphoblastic leukemia (ALL) is associated with high reinduction
mortality, chemotherapy resistance, and rapid progression leading to death. Vincristine …

Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non‐Hodgkin lymphoma: report of the pivotal phase 2 study

…, R Gascoyne, B Lu, SR Deitcher… - … Journal of the …, 2009 - Wiley Online Library
BACKGROUND: Marqibo, a sphingosomal/cholesterol encapsulation of vincristine sulfate has
targeted, increased, and sustained delivery of vincristine to tumor tissues. A phase 2, open…

Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease

…, MG Cameron, L Rybicki, SR Deitcher… - … Journal of the …, 2004 - Wiley Online Library
BACKGROUND Venous thromboembolic disease (VTD) is a recently recognized complication
of thalidomide in combination therapy for patients with multiple myeloma (MM). The …

The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review

SR Deitcher, MPV Gomes - … International Journal of the …, 2004 - Wiley Online Library
BACKGROUND Tamoxifen therapy for patients with breast carcinoma is perceived as an
independent risk factor for venous thromboembolic events (VTE), but the risk associated with …

[HTML][HTML] Hypercoagulable state mutation analysis in white patients with early first-trimester recurrent pregnancy loss

WH Kutteh, VM Park, SR Deitcher - Fertility and Sterility, 1999 - Elsevier
Objective: Antiphospholipid antibodies (APA) and other coagulation abnormalities have
been associated with an increased risk of venous, arterial, and placental thrombosis and …

Virchow's triad revisited

DJ Brotman, SR Deitcher, GYH Lip… - Southern medical …, 2004 - go.gale.com
To the Editor: Three factors predispose patients to thrombosis--stasis, hypercoagulability, and
vessel wall injury--which have commonly been termed Virchow's triad. However, this is not …